Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

B cell tetherin: a flow-cytometric cell-specific assay for response to Type-I interferon predicts clinical features and flares in SLE.

El-Sherbiny YM, Md Yusof MY, Psarras A, Hensor EMA, Kabba KZ, Dutton K, Mohamed AAA, Elewaut D, McGonagle D, Tooze R, Doody G, Wittmann M, Emery P, Vital EM.

Arthritis Rheumatol. 2019 Dec 5. doi: 10.1002/art.41187. [Epub ahead of print]

PMID:
31804007
2.

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus.

Md Yusof MY, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, Vital EM.

Lupus. 2019 Oct;28(11):1320-1328. doi: 10.1177/0961203319873977. Epub 2019 Sep 14.

3.

Non-invasive Approaches for the Diagnosis of Autoimmune/Autoinflammatory Skin Diseases-A Focus on Psoriasis and Lupus erythematosus.

Berekméri A, Tiganescu A, Alase AA, Vital E, Stacey M, Wittmann M.

Front Immunol. 2019 Aug 21;10:1931. doi: 10.3389/fimmu.2019.01931. eCollection 2019. Review.

4.

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature.

Shalbaf M, Alase AA, Berekmeri A, Md Yusof MY, Pistolic J, Goodfield MJ, Edward S, Botchkareva NV, Stacey M, Vital EM, Wittmann M.

Lupus Sci Med. 2019 Jul 14;6(1):e000328. doi: 10.1136/lupus-2019-000328. eCollection 2019.

5.

Rgma-Induced Neo1 Proteolysis Promotes Neural Tube Morphogenesis.

Brown S, Jayachandran P, Negesse M, Olmo V, Vital E, Brewster R.

J Neurosci. 2019 Sep 18;39(38):7465-7484. doi: 10.1523/JNEUROSCI.3262-18.2019. Epub 2019 Aug 9.

PMID:
31399534
6.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
7.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

8.

Work participation, mobility and foot symptoms in people with systemic lupus erythematosus: findings of a UK national survey.

Stevens MJ, Walker-Bone K, Culliford DJ, Alcacer-Pitarch B, Blake A, Hopkinson N, Teh LS, Vital EM, Edwards CJ, Williams AE, Cherry L.

J Foot Ankle Res. 2019 Apr 29;12:26. doi: 10.1186/s13047-019-0335-0. eCollection 2019.

9.

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.

Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S.

Arthritis Rheumatol. 2019 Nov;71(11):1812-1823. doi: 10.1002/art.40937. Epub 2019 Sep 26.

PMID:
31131994
10.

Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort.

Hassan SU, Mahmoud K, Vital EM.

Ann Rheum Dis. 2019 Apr 25. pii: annrheumdis-2019-215411. doi: 10.1136/annrheumdis-2019-215411. [Epub ahead of print] No abstract available.

PMID:
31023655
11.

Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE.

Dutton K, Savic S, Owen R, Vital E.

BMJ Case Rep. 2019 Jan 4;12(1). pii: e226083. doi: 10.1136/bcr-2018-226083.

PMID:
30612104
12.

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus.

Mahmoud K, Zayat AS, Yusof Y, Hensor E, Conaghan PG, Emery P, Vital EM.

Rheumatology (Oxford). 2019 Jan 3. doi: 10.1093/rheumatology/key422. [Epub ahead of print]

13.

Publisher Correction: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features.

El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, Mohamed AAA, McGonagle D, Wittmann M, Emery P, Vital EM.

Sci Rep. 2018 Oct 1;8(1):14846. doi: 10.1038/s41598-018-33062-1.

14.

Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus.

Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA, Wakefield RJ, Conaghan PG, Edwards CJ, Emery P, Vital EM.

Rheumatology (Oxford). 2019 Feb 1;58(2):304-312. doi: 10.1093/rheumatology/key277.

15.

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.

Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, Zayat AS, Shalbaf M, Alase A, Wittmann M, Emery P, Vital EM.

Ann Rheum Dis. 2018 Oct;77(10):1432-1439. doi: 10.1136/annrheumdis-2018-213386. Epub 2018 Jun 21.

16.

A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features.

El-Sherbiny YM, Psarras A, Md Yusof MY, Hensor EMA, Tooze R, Doody G, Mohamed AAA, McGonagle D, Wittmann M, Emery P, Vital EM.

Sci Rep. 2018 Apr 11;8(1):5793. doi: 10.1038/s41598-018-24198-1. Erratum in: Sci Rep. 2018 Oct 1;8(1):14846.

17.

The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus.

Pentony P, Duquenne L, Dutton K, Mankia K, Gul H, Vital E, Emery P.

Discov Med. 2017 Nov;24(133):191-200. Review.

18.

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.

McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2018 Mar 1;57(3):470-479. doi: 10.1093/rheumatology/kex395.

19.

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Romão VC, Vital EM, Fonseca JE, Buch MH.

Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3. Review.

20.

Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab.

Daniel A, Bagnato G, Vital E, Del Galdo F.

BMJ Case Rep. 2017 Oct 20;2017. pii: bcr-2017-222339. doi: 10.1136/bcr-2017-222339.

21.

Use of Immunolabeling to Analyze Stable, Dynamic, and Nascent Microtubules in the Zebrafish Embryo.

McFarland RJ, Brown SP, Vital E, Werner JM, Brewster RM.

J Vis Exp. 2017 Sep 20;(127). doi: 10.3791/55792.

22.

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.

Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM.

Ann Rheum Dis. 2017 Nov;76(11):1829-1836. doi: 10.1136/annrheumdis-2017-211191. Epub 2017 Jul 6.

23.

Musculoskeletal manifestations of systemic lupus erythmatosus.

Mahmoud K, Zayat A, Vital EM.

Curr Opin Rheumatol. 2017 Sep;29(5):486-492. doi: 10.1097/BOR.0000000000000421. Review.

PMID:
28661935
24.

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2017 Jun 1;56(6):1049. doi: 10.1093/rheumatology/kex218. No abstract available.

25.

Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise.

Glinatsi D, Bird P, Gandjbakhch F, Haavardsholm EA, Peterfy CG, Vital EM, Emery P, Conaghan PG, Østergaard M.

J Rheumatol. 2017 Nov;44(11):1688-1693. doi: 10.3899/jrheum.161097. Epub 2017 May 1.

26.

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S, Emery P.

Rheumatology (Oxford). 2017 Aug 1;56(8):1348-1357. doi: 10.1093/rheumatology/kex072.

27.

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2017 Jun 1;56(6):1041-1043. doi: 10.1093/rheumatology/kex044. No abstract available. Erratum in: Rheumatology (Oxford). 2017 Jun 1;56(6):1049.

28.

Patients' experiences of lupus-related foot problems: a qualitative investigation.

Williams AE, Blake A, Cherry L, Alcacer-Pitarch B, Edwards CJ, Hopkinson N, Vital EMJ, Teh LS.

Lupus. 2017 Oct;26(11):1174-1181. doi: 10.1177/0961203317696590. Epub 2017 Mar 9.

PMID:
28420063
29.

Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.

Psarras A, Emery P, Vital EM.

Rheumatology (Oxford). 2017 Oct 1;56(10):1662-1675. doi: 10.1093/rheumatology/kew431. Review.

30.

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferracioli G, Soubrier M, Ly B, Chavez HH, Taoufik Y, Dougados M, Mariette X.

Arthritis Res Ther. 2017 Jan 23;19(1):11. doi: 10.1186/s13075-017-1221-4. No abstract available.

31.

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X.

Arthritis Res Ther. 2016 Dec 13;18(1):294. Erratum in: Arthritis Res Ther. 2017 Jan 23;19(1):11.

32.

The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey.

Cherry L, Alcacer-Pitarch B, Hopkinson N, Teh LS, Vital EM, Edwards CJ, Blake A, Williams AE.

Lupus. 2017 Apr;26(4):410-416. doi: 10.1177/0961203316670730. Epub 2016 Sep 30.

PMID:
27687022
33.

Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity.

Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM, Vital EM, Westhead DR, Tooze RM, Doody GM.

J Immunol. 2016 Aug 15;197(4):1447-59. doi: 10.4049/jimmunol.1600624. Epub 2016 Jun 29.

34.

An Investigation into the Scale and Impact of Self-Reported Foot Problems Associated with Systemic Lupus Erythematosus: A Study Protocol and Survey Questionnaire Development.

Williams AE, Cherry L, Blake A, Alcacer-Pitarch B, Edwards C, Hopkinson N, Vital E, Teh LS.

Musculoskeletal Care. 2016 Jun;14(2):110-5. doi: 10.1002/msc.1119. Epub 2015 Sep 7.

PMID:
27264548
35.

Microtubule-associated protein 1b is required for shaping the neural tube.

Jayachandran P, Olmo VN, Sanchez SP, McFarland RJ, Vital E, Werner JM, Hong E, Sanchez-Alberola N, Molodstov A, Brewster RM.

Neural Dev. 2016 Jan 18;11:1. doi: 10.1186/s13064-015-0056-4.

36.

The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review.

Zayat AS, Md Yusof MY, Wakefield RJ, Conaghan PG, Emery P, Vital EM.

Rheumatology (Oxford). 2016 Mar;55(3):485-94. doi: 10.1093/rheumatology/kev343. Epub 2015 Oct 7. Review.

37.

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Md Yusof MY, Vital EM, Buch MH.

Curr Rheumatol Rep. 2015 Oct;17(10):65. doi: 10.1007/s11926-015-0539-7. Review.

38.

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism.

Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, Wittmann M.

J Invest Dermatol. 2015 Dec;135(12):2935-2943. doi: 10.1038/jid.2015.317. Epub 2015 Aug 19.

39.

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Sep;74(9):1734-8. doi: 10.1136/annrheumdis-2014-206496. Epub 2015 Apr 8.

40.

Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.

Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield M, Emery P.

Arthritis Rheumatol. 2015 Jun;67(6):1586-91. doi: 10.1002/art.39085.

41.

Law of the vital few: choosing variables of disease activity in rheumatoid arthritis.

Dumitru B, Buch M, Vital EM.

J Rheumatol. 2014 Nov;41(11):2097-8. doi: 10.3899/jrheum.141038. No abstract available.

PMID:
25362705
42.

Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic?

Ponchel F, Burska AN, Vital EM.

Pharmacogenomics. 2014 Jul;15(10):1275-9. doi: 10.2217/pgs.14.79. No abstract available.

43.

Biologics in systemic lupus erythematosus: current options and future perspectives.

Md Yusof MY, Vital EM, Emery P.

Br J Hosp Med (Lond). 2014 Aug;75(8):440, 442-7. doi: 10.12968/hmed.2014.75.8.440. Review.

PMID:
25111095
44.

Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.

Vital EM, Md Yusof MY, Emery P.

Arthritis Care Res (Hoboken). 2014 Oct;66(10):1591-3. doi: 10.1002/acr.22379. No abstract available.

45.

Autoantibodies to posttranslational modifications in rheumatoid arthritis.

Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, Vital E, Nissim A, Winyard PG, Emery P, Ponchel F.

Mediators Inflamm. 2014;2014:492873. doi: 10.1155/2014/492873. Epub 2014 Mar 23. Review.

46.

Response to Dr Bredemeier's letter.

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P.

Ann Rheum Dis. 2014 Jun;73(6):e34. doi: 10.1136/annrheumdis-2014-205405. Epub 2014 Mar 14. No abstract available.

PMID:
24632007
47.

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Jun;74(6):1195-201. doi: 10.1136/annrheumdis-2013-204544. Epub 2014 Jan 17.

PMID:
24443001
48.

Response to: 'Which B-cell subset should we target in lupus?' by Ferraccioli and Houssiau.

Arumugakani G, Vital EM, Md Yusof MY, McGonagle DG, Emery P.

Ann Rheum Dis. 2014 Apr;73(4):e20. doi: 10.1136/annrheumdis-2013-205096. Epub 2014 Jan 15. No abstract available.

PMID:
24431390
49.

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.

Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2.

PMID:
24385201
50.

An immunological biomarker to predict MTX response in early RA.

Ponchel F, Goëb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, Burska A, Vital EM, Harrison S, Conaghan PG, Hensor E, Emery P.

Ann Rheum Dis. 2014 Nov;73(11):2047-53. doi: 10.1136/annrheumdis-2013-203566. Epub 2013 Aug 29.

PMID:
23989988

Supplemental Content

Support Center